Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5548215 | 0.94 | HSD11B1 (0.40) | HSD11B1MEN1KMT2AMLYCDSIGMAR1 | |
| SCHEMBL13675464 | 0.83 | PTGDR2 (0.44) | HSD11B1MEN1KMT2A | |
| SCHEMBL4513549 | 0.81 | HSD11B1 (0.38) | HSD11B1CHRM2CHRM3P2RX7OPRM1 | |
| SCHEMBL4514751 | 0.77 | PTGDR2 (0.44) | HSD11B1MEN1KMT2A | |
| SCHEMBL4509610 | 0.77 | ALDH1A1 (0.36) | HSD11B1MEN1KMT2AOPRD1OPRK1 | |
| SCHEMBL4507389 | 0.77 | HSD11B1 (0.49) | HSD11B1KMT2ASIGMAR1P2RX7OPRK1 | |
| SCHEMBL14365228 | 0.76 | HSD11B1 (0.39) | HSD11B1P2RX7OPRM1OPRD1OPRK1 | |
| SCHEMBL4525978 | 0.75 | HSD11B1 (0.46) | HSD11B1KMT2ASIGMAR1P2RX7OPRK1 | |
| SCHEMBL4515881 | 0.75 | HSD11B1 (0.57) | HSD11B1KMT2AOPRD1 | |
| SCHEMBL13674550 | 0.74 | OPRM1 (0.42) | HSD11B1MEN1KMT2AOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885MEN1 1254/4885KMT2A 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.